(CNW) Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

MONTREAL, /CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1 ...

Harmony Biosciences Guides to Over $1 Billion in WAKIX(R) Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...
PharmiWeb

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

WAKIX 2025 Preliminary Net Revenue of ~$868 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in NarcolepsyOn Track to Extend the Pitolisant Franchise ...
PharmiWeb

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...
The Manila Times

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated ...

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will ...
Newswire

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

Study demonstrated clear target engagement at both tested doses Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases Phase 2a ASPIRE-HF study to commence enrollment in 2026 ...

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was named Best New Drug at the ...
emjreviews.com

Incidence and Cumulative Risk Factors for Prolonged Corrected QT Interval in Patients with Liver Cirrhosis Receiving Fluoroquinolone Prophylaxis

Dhand has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Merck and Eurofins Viracor. The other authors have declared no ...
ahajournals.org

Abstract 4365304: Prolonged QT Interval After Cryptogenic Stroke and Risk of Recurrent Stroke in the ARCADIA Trial

Introduction: Prolonged QT interval has been associated with first stroke of any type in the general population. Whether QT prolongation predicts recurrent stroke is unknown. Hypothesis: We ...
Seeking Alpha

Kura Oncology's Ziftomenib Poised For Differentiation

Kura Oncology is reiterated as a strong buy, due to Ziftomenib's potential best-in-class safety profile in NPM1-mutated AML. Recent FDA approval of Syndax's Revuforj included a boxed warning for ...